WORLD CONGRESS ON ADVANCED PHARMACY AND CLINICAL RESEARCH

December 2-3, 2022 | Ireland

WORLD CONGRESS
SCIENCENET cordially invite you to attend the World Congress on Advanced Pharmacy and Clinical Research slated on 2nd-3rd December 2022 at Dublin,Ireland . We welcome all scientists, scholars, students, industrialists to attend and explore their knowledge in the field of World Congress on Advanced Pharmacy and Clinical Research.

Spotlight

In the last few years, pharmaceutical companies have become increasingly interested in biomarkers and their incorporation into company drug development programmes and use as companion tests for targeted therapeutics. Identifying patients that will benefit from a drug and eliminating those that will not is increasingly important. A simple analysis of the number of biomarker deals recorded in PharmaVentures' PharmaDeals database shows a rise from just seven in 2001 to 130 in 2007. There are a number of drivers for this, and these include: the increasing cost of drug development and associated decline in new molecular entities (NMEs) achieving registration; patient and regulatory authorities requesting upfront evidence of therapeutic benefit; and reimbursing bodies requiring proof of likely beneficial outcomes before payment. One would imagine that the combination of these factors would result in a highly positive outlook for biomarker researchers and developers. However, the situation is not as simple as it appears because, despite the factors listed above, it is hard to capture the value created by the addition of a biomarker into the drug development or patient identification process, and thus to apportion returns from subsequent commercialization of the drug and/or biomarker.


OTHER PAST CONFERENCES

Pharma Industry & pharmaceuticals

October 3-4, 2022 | France

After a decent assembling of past drug organization gatherings, drug Conferences group merrily invites individuals from everyplace the planet to venture out to " third International meeting on Pharma Industry and drugs"

Drug Discovery and Drug Development

November 24-25, 2022 | USA

Allied Academies every year hosts interdisciplinary international conferences worldwide oncutting-edge basic and applied research in life sciences, Pharma,Medicine, Healthcareand Nursing deliveredby the best talents in industry and academia.

World Congress on Pharmaceutical Chemistry

November 10-11, 2022 | Germany

The main aim of Pharmaceutical Chemistry conference 2022 provides interaction between Pharmacists, Drug delivery experts, Pharma industries, R&D department, Young Researchers, Ph.D. scholars,

The World’s Leading Extreme Medicine Conference

November 19-21, 2022 | USA

We have brought together the best experts and thought leaders in extreme medicine, covering 14 different themes, to deliver 3 days of world class content.

Spotlight

In the last few years, pharmaceutical companies have become increasingly interested in biomarkers and their incorporation into company drug development programmes and use as companion tests for targeted therapeutics. Identifying patients that will benefit from a drug and eliminating those that will not is increasingly important. A simple analysis of the number of biomarker deals recorded in PharmaVentures' PharmaDeals database shows a rise from just seven in 2001 to 130 in 2007. There are a number of drivers for this, and these include: the increasing cost of drug development and associated decline in new molecular entities (NMEs) achieving registration; patient and regulatory authorities requesting upfront evidence of therapeutic benefit; and reimbursing bodies requiring proof of likely beneficial outcomes before payment. One would imagine that the combination of these factors would result in a highly positive outlook for biomarker researchers and developers. However, the situation is not as simple as it appears because, despite the factors listed above, it is hard to capture the value created by the addition of a biomarker into the drug development or patient identification process, and thus to apportion returns from subsequent commercialization of the drug and/or biomarker.

resources